Ana Luísa Rodriguez Gini

Ms. Ana Luísa Rodriguez Gini

Drugs and Medicines, School of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara, São Paulo, Brazil
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Mateus SouzaMateus Souza
Mateus Souza
Ana Luísa Rodriguez GiniAna Luísa Rodriguez Gini
Ana Luísa Rodriguez Gini
JMJhonnathan Alves Moura
Jhonnathan Alves Moura
CSCauê Benito Scarim
Cauê Benito Scarim
CCChung Man Chin
Chung Man Chin
Jean Leandro Dos SantosJean Leandro Dos Santos
Jean Leandro Dos Santos
Absorption and permeability are critical physicochemical parameters that must be balanced to achieve optimal drug uptake. These key factors are closely linked to the maximum absorbable dose required to provide appropriate plasma levels of drugs. Among the various strategies employed to enhance drug solubility and permeability, prodrug design stands out as a highly effective and versatile approach for improving physicochemical properties and enabling the optimization of biopharmaceutical and pharmacokinetic parameters while mitigating adverse effects. Prodrugs are compounds with reduced or no activity that, through bio-reversible chemical or enzymatic processes, release an active parental drug. The application of this technology has led to significant advancements in drug optimization during the design phase, and it offers broad potential for further development. Notably, approximately 13% of the drugs approved by the U.S. Food and Drug Administration (FDA) between 2012 and 2022 were prodrugs. In this review article, we will explore the application of prodrug strategies to enhance permeability, describing examples of market drugs. We also describe the use of the prodrug approach to optimize PROteolysis TArgeting Chimeras (PROTACs) permeability by using conjugation technologies. We will highlight some new technologies in prodrugs to enrich permeability properties, contributing to developing new effective and safe prodrugs.

16 April 2025 in Molecules
Verified
Journal Article
Open access
PDF file
PCPamela Cunha
Pamela Cunha
Ana Luísa Rodriguez GiniAna Luísa Rodriguez Gini
Ana Luísa Rodriguez Gini
CCChung Man Chin
Chung Man Chin
Jean Leandro Dos SantosJean Leandro Dos Santos
Jean Leandro Dos Santos
CSCauê Benito Scarim
Cauê Benito Scarim
Neglected tropical diseases (NTDs), including Chagas disease, human African trypanosomiasis (HAT), leishmaniasis, and malaria, remain a major global health challenge, disproportionately affecting low-income populations. Current therapies for these diseases suffer from significant limitations, such as reduced efficacy, high toxicity, and emerging parasite resistance, highlighting the urgent need for new therapeutic strategies. In response, substantial efforts have been directed toward the synthesis of new molecules with improved potency, selectivity, and pharmacokinetic profiles. However, despite many of these compounds exhibiting favorable ADMET (absorption, distribution, metabolism, excretion, and toxicity) profiles and strong in vitro activity, their translation into in vivo models remains limited. Key challenges include the lack of investment, the absence of fully representative experimental models, and difficulties in extrapolating cell-based assay results to more complex biological systems. In this review, we analyzed the latest advancements (2019–2024) in the development of these compound classes, correlating predictive parameters with their observed biological activity. Among these parameters, we highlighted the partition coefficient (LogP), which measures a compound’s lipophilicity and influences its ability to cross biological membranes, and Caco-2 cell permeability, an in vitro model widely used to predict intestinal drug absorption. Additionally, we prioritized the most promising molecules and structural classes for pharmaceutical development, discussing structure–activity relationships (SARs) and the remaining challenges that must be overcome to enable the clinical application of these compounds in the treatment of NTDs.

19 June 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Ana Luísa Rodriguez GiniAna Luísa Rodriguez Gini
Ana Luísa Rodriguez Gini
PCPamela Cunha
Pamela Cunha
EJEmilio Emilio João
Emilio Emilio João
CCChung Man Chin
Chung Man Chin
Jean Leandro Dos SantosJean Leandro Dos Santos
Jean Leandro Dos Santos
CSCauê Benito Scarim
Cauê Benito Scarim
Chagas disease, caused by the protozoan parasite Trypanosoma cruzi (T. cruzi), continues to pose significant public health challenges due to the toxicity, poor tolerability, and limited efficacy of current treatments. Targeted protein degradation (TPD) using proteolysis-targeting chimeras (PROTACs) represents a novel therapeutic avenue by leveraging the ubiquitin–proteasome system to selectively degrade essential parasite proteins. This review introduces the conceptual framework of “TrypPROTACs” as a prospective strategy for T. cruzi, integrating a comprehensive analysis of druggable targets across critical biological pathways, including ergosterol biosynthesis, redox metabolism, glycolysis, nucleotide synthesis, protein kinases, molecular chaperones such as heat shock protein 90 (Hsp90), and epigenetic regulators such as T. cruzi bromodomain factor 3 (TcBDF3). It is important to note that no TrypPROTAC compound has yet been synthesized or experimentally validated in T. cruzi; the approach discussed herein remains theoretical and forward-looking. Representative inhibitors for each target class are compiled, highlighting potency, selectivity, and structural features relevant to ligand design. We also examine the parasite’s ubiquitination machinery and compare it to the human system to identify putative E3 ubiquitin ligases. Key aspects of linker engineering and ternary complex stabilization are discussed, alongside potential validation techniques such as the cellular thermal shift assay (CETSA) and bioluminescence resonance energy transfer (NanoBRET). Collectively, these insights outline a roadmap for the rational design of TrypPROTACs and support the feasibility of expanding targeted protein degradation strategies to neglected tropical diseases.

24 February 2022 in Revista Brasileira de Ginecologia e Obstetrícia
Verified
Journal Article
Open access
PDF file
RLRosa Camila Lucchetta
Rosa Camila Lucchetta
ILIsabele Held Lemos
Isabele Held Lemos
Ana Luísa Rodriguez GiniAna Luísa Rodriguez Gini
Ana Luísa Rodriguez Gini
SCSophia de Andrade Cavicchioli
Sophia de Andrade Cavicchioli
MFMarcela Forgerini
Marcela Forgerini
PMPatricia de Carvalho Mastroianni
Patricia de Carvalho Mastroianni
Objective To estimate the prevalence of inadequate vitamin D level and its associated factors for women of childbearing age in Brazil. Methods A systematic review was conducted (last updated May 2020). Meta-analyses were performed using the inverse-variance for fixed models with summary proportion calculation by Freeman-Tukey double arcsine. Reporting and methodological quality were assessed using the Joanna Briggs Institute tool for prevalence studies. Results Our review identified 31 studies, comprising 4,006 participants. All the studies had at least one weakness, mainly due to the use of convenience sampling and small sample size. The overall prevalence of vitamin D deficiency, insufficiency, and both deficiency and insufficiency were 35% (confidence interval, 95%CI: 34–37%), 42% (95%CI: 41–44%), and 72% (95%CI: 71–74%), respectively. Conclusion Although the magnitude of the prevalence of inadequate levels of vitamin D is uncertain, the evidence suggests that presence of vitamin D deficiency or insufficiency in women of reproductive age can cause moderate to severe problems.

25 January 2025 in Molecules
Verified
Journal Article
Open access
PDF file
Stéphanie Rochetti do AmaralStéphanie Rochetti do Amaral
Stéphanie Rochetti do Amaral
MFMariza Aires Fernandes
Mariza Aires Fernandes
FHFelipe Falcão Haddad
Felipe Falcão Haddad
Ana Luísa Rodriguez GiniAna Luísa Rodriguez Gini
Ana Luísa Rodriguez Gini
CSCauê Benito Scarim
Cauê Benito Scarim
FPFernando L. Primo
Fernando L. Primo
The photosensitizer (PS) in the Photodynamic Therapy (PDT) field represents a key factor, being directly connected to the therapeutic efficacy of the process. Chlorin e6 is a second-generation photosensitizer, approved by the FDA with the most desired clinical properties for PDT applications, presenting high reactive oxygen species (ROS) generation and proven anticancer properties. However, hydrophobicity is a major limitation, leading to poor biodistribution. To overcome this condition, the present work developed an up-to-date nanoemulsion incorporating Ce6 in a new nanosystem (Ce6/NE). A comprehensive study of physicochemical properties, stability, fluorescence characteristics, the in vitro release profile, in vivo and ex vivo biocompatibility, and ex vivo efficacy was established. The nanoemulsions showed the desired particle size and stability over six months, with no spectroscopic or photophysical alterations. Uptake studies demonstrated the internalization of the Ce6/NE in monolayers, with biocompatibility at the lowest concentrations. The HET-CAM assay, however, revealed a higher biocompatibility range, also indicating Ce6/NE’s potential for cancer treatment through antiangiogenic studies. These findings highlight the use of a new promising photosensitizer for PDT modulated with nanotechnology that promotes low toxicity, higher bioavailability, and site-specific delivery.

14 January 2021 in Journal of Health & Biological Sciences
Verified
Journal Article
Open access
PDF file
RLRosa Camila Lucchetta
Rosa Camila Lucchetta
ILIsabele Held Lemos
Isabele Held Lemos
ASAna Caroline Silva Santos
Ana Caroline Silva Santos
HBHelena Hiemisch Lobo Borba
Helena Hiemisch Lobo Borba
ABAline De Fátima Bonetti
Aline De Fátima Bonetti
PMPatricia De Carvalho Mastroianni
Patricia De Carvalho Mastroianni
Objetivo: mapear os possíveis desfechos de longo prazo da COVID-19 no mundo. Métodos: em acordo com as recomendações do Joanna Briggs Institute, foi realizada uma revisão sistemática de escopo de estudos experimentais e observacionais com busca nas bases de dados PubMed e Scopus, complementada por busca manual. Resultados: de 5.325 registros, 121 atenderam aos critérios de elegibilidade, os quais incluíram 1.638 recuperados da COVID-19. Foram identificados 52 potenciais desfechos de longo prazo da COVID-19, principalmente disfunção olfatória (n=605), disfunção gustativa (n=372), dispneia (n=233) e lesões pulmonares (n=225). Entre os cuidados de longo prazo, destacam-se início de terapia medicamentosa, terapia de substituição renal e amputação. Conclusão: foram mapeados 52 possíveis desfechos de longo prazo da COVID-19 e recomendações de continuação de cuidados, que variaram de manifestações leves a graves com duração menor ou igual a um mês e maior que um mês.